Literature DB >> 10452615

Drug resistance mutations can effect dimer stability of HIV-1 protease at neutral pH.

D Xie1, S Gulnik, E Gustchina, B Yu, W Shao, W Qoronfleh, A Nathan, J W Erickson.   

Abstract

The monomer-dimer equilibrium for the human immunodeficiency virus type 1 (HIV-1) protease has been investigated under physiological conditions. Dimer dissociation at pH 7.0 was correlated with a loss in beta-sheet structure and a lower degree of ANS binding. An autolysis-resistant mutant, Q7K/L33I/L63I, was used to facilitate sedimentation equilibrium studies at neutral pH where the wild-type enzyme is typically unstable in the absence of bound inhibitor. The dimer dissociation constant (KD) of the triple mutant was 5.8 microM at pH 7.0 and was below the limit of measurement (approximately 100 nM) at pH 4.5. Similar studies using the catalytically inactive D25N mutant yielded a KD value of 1.0 microM at pH 7.0. These values differ significantly from a previously reported value of 23 nM obtained indirectly from inhibitor binding measurements (Darke et al., 1994). We show that the discrepancy may result from the thermodynamic linkage between the monomer-dimer and inhibitor binding equilibria. Under conditions where a significant degree of monomer is present, both substrates and competitive inhibitors will shift the equilibrium toward the dimer, resulting in apparent increases in dimer stability and decreases in ligand binding affinity. Sedimentation equilibrium studies were also carried out on several drug-resistant HIV-1 protease mutants: V82F, V82F/I84V, V82T/I84V, and L90M. All four mutants exhibited reduced dimer stability relative to the autolysis-resistant mutant at pH 7.0. Our results indicate that reductions in drug affinity may be due to the combined effects of mutations on both dimer stability and inhibitor binding.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10452615      PMCID: PMC2144419          DOI: 10.1110/ps.8.8.1702

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  26 in total

Review 1.  Proteolytic processing and particle maturation.

Authors:  V M Vogt
Journal:  Curr Top Microbiol Immunol       Date:  1996       Impact factor: 4.291

2.  Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure.

Authors:  S V Gulnik; L I Suvorov; B Liu; B Yu; B Anderson; H Mitsuya; J W Erickson
Journal:  Biochemistry       Date:  1995-07-25       Impact factor: 3.162

3.  Kinetic assay for HIV proteinase subunit dissociation.

Authors:  P Kuzmic
Journal:  Biochem Biophys Res Commun       Date:  1993-03-31       Impact factor: 3.575

4.  Dissociation and association of the HIV-1 protease dimer subunits: equilibria and rates.

Authors:  P L Darke; S P Jordan; D L Hall; J A Zugay; J A Shafer; L C Kuo
Journal:  Biochemistry       Date:  1994-01-11       Impact factor: 3.162

Review 5.  Subsite preferences of retroviral proteinases.

Authors:  B M Dunn; A Gustchina; A Wlodawer; J Kay
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

Review 6.  Stability of dimeric retroviral proteases.

Authors:  P L Darke
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

Review 7.  Structure-based inhibitors of HIV-1 protease.

Authors:  A Wlodawer; J W Erickson
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

8.  Use of protein unfolding studies to determine the conformational and dimeric stabilities of HIV-1 and SIV proteases.

Authors:  S K Grant; I C Deckman; J S Culp; M D Minnich; I S Brooks; P Hensley; C Debouck; T D Meek
Journal:  Biochemistry       Date:  1992-10-06       Impact factor: 3.162

9.  Two-step binding mechanism for HIV protease inhibitors.

Authors:  E S Furfine; E D'Souza; K J Ingold; J J Leban; T Spector; D J Porter
Journal:  Biochemistry       Date:  1992-09-01       Impact factor: 3.162

10.  The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties.

Authors:  A M Mildner; D J Rothrock; J W Leone; C A Bannow; J M Lull; I M Reardon; J L Sarcich; W J Howe; C S Tomich; C W Smith
Journal:  Biochemistry       Date:  1994-08-16       Impact factor: 3.162

View more
  22 in total

1.  Reversible oxidative modification as a mechanism for regulating retroviral protease dimerization and activation.

Authors:  David A Davis; Cara A Brown; Fonda M Newcomb; Emily S Boja; Henry M Fales; Joshua Kaufman; Stephen J Stahl; Paul Wingfield; Robert Yarchoan
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Structure-based phenotyping predicts HIV-1 protease inhibitor resistance.

Authors:  Mark D Shenderovich; Ron M Kagan; Peter N R Heseltine; Kal Ramnarayan
Journal:  Protein Sci       Date:  2003-08       Impact factor: 6.725

3.  Patterns of Human Immunodeficiency Virus type 1 recombination ex vivo provide evidence for coadaptation of distant sites, resulting in purifying selection for intersubtype recombinants during replication.

Authors:  Andrea Galli; Mary Kearney; Olga A Nikolaitchik; Sloane Yu; Mario P S Chin; Frank Maldarelli; John M Coffin; Vinay K Pathak; Wei-Shau Hu
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

4.  Design of HIV-1-PR inhibitors that do not create resistance: blocking the folding of single monomers.

Authors:  Ricardo A Broglia; Guido Tiana; Ludovico Sutto; Davide Provasi; Fabio Simona
Journal:  Protein Sci       Date:  2005-10       Impact factor: 6.725

5.  Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease.

Authors:  Jane M Sayer; Fengling Liu; Rieko Ishima; Irene T Weber; John M Louis
Journal:  J Biol Chem       Date:  2008-02-15       Impact factor: 5.157

6.  Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity.

Authors:  Jennifer E Foulkes; Moses Prabu-Jeyabalan; Deyna Cooper; Gavin J Henderson; Janera Harris; Ronald Swanstrom; Celia A Schiffer
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

7.  Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance.

Authors:  Madhavi N L Nalam; Akbar Ali; G S Kiran Kumar Reddy; Hong Cao; Saima G Anjum; Michael D Altman; Nese Kurt Yilmaz; Bruce Tidor; Tariq M Rana; Celia A Schiffer
Journal:  Chem Biol       Date:  2013-09-05

8.  Insight into the folding inhibition of the HIV-1 protease by a small peptide.

Authors:  Massimiliano Bonomi; Francesco L Gervasio; Guido Tiana; Davide Provasi; Ricardo A Broglia; Michele Parrinello
Journal:  Biophys J       Date:  2007-06-15       Impact factor: 4.033

9.  Multiple routes and milestones in the folding of HIV-1 protease monomer.

Authors:  Massimiliano Bonomi; Alessandro Barducci; Francesco L Gervasio; Michele Parrinello
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

10.  Human immunodeficiency virus (HIV) type 1 transframe protein can restore activity to a dimerization-deficient HIV protease variant.

Authors:  Nathalie Dautin; Gouzel Karimova; Daniel Ladant
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.